Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Docetaxel and Estramustine in High Risk Localized Prostate Cancer
NCT00193271Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Aug 2004
- Primary completion
- May 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, estramustine in prostate cancer (PCa), sponsored by SCRI Development Innovations. Started Aug 2004; status: completed.
02
Drugs
docetaxelestramustine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00193271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193271.